CD27 expression is a clinically accessible biomarker for predicting immunotherapy response in melanoma - PubMed
3 hours ago
- #immunotherapy
- #biomarker
- #melanoma
- CD27 expression is identified as a biomarker for predicting immunotherapy response in melanoma.
- High CD27 mRNA expression correlates with immune checkpoint genes, enhanced immune infiltration, and favorable prognosis.
- CD27 demonstrated strong predictive performance in ROC curve analysis with AUC values of 0.763 and 0.659 in different datasets.
- Validation in a retrospective cohort showed CD27 mRNA and protein levels surpassing PD-L1 in predictive value.
- CD27 IHC showed 69.8% sensitivity compared to 27.9% for PD-L1 in identifying responders.
- Patients with CD27-positive tumors exhibited significantly longer progression-free survival.
- CD27 is expressed in CD45RO memory T cells, highlighting its role in anti-tumor immunity.
- A pending patent application related to CD27 as a predictive biomarker has been filed.